At the time of writing, Globus Medical Inc [GMED] stock is trading at $53.68, up 0.96%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The GMED shares have gain 3.59% over the last week, with a monthly amount drifted -3.03%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 20, February 2024, Globus Medical Reports Fourth Quarter and Full Year 2023 Results. In a post published today on Yahoo Finance, Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, 2023.
From an analyst’s perspective:
Globus Medical Inc [NYSE: GMED] stock has seen the most recent analyst activity on March 18, 2024, when BTIG Research upgraded its rating to a Buy but kept the price target unchanged to $60 for it. Previously, ROTH MKM started tracking the stock with Buy rating on October 20, 2023, and set its price target to $75. On September 19, 2023, upgrade upgraded it’s rating to Buy but maintained its price target of $61 on the stock. Canaccord Genuity upgraded its rating to a Buy but stick to its price target of $67 on March 30, 2023. BofA Securities downgraded its rating to a Underperform and reduced its price target to $63 on February 13, 2023. Wells Fargo downgraded its rating to Equal Weight for this stock on February 10, 2023, but kept the price target unchanged to $67. In a note dated February 10, 2023, Truist downgraded an Hold rating on this stock and revised its target price from $85 to $70.
For the past year, the stock price of Globus Medical Inc fluctuated between $43.38 and $62.88. Currently, Wall Street analysts expect the stock to reach $78.69 within the next 12 months. Globus Medical Inc [NYSE: GMED] shares were valued at $53.68 at the most recent close of the market. An investor can expect a potential return of 46.59% based on the average GMED price forecast.
Analyzing the GMED fundamentals
According to Globus Medical Inc [NYSE:GMED], the company’s sales were 1.57B for trailing twelve months, which represents an 124.60% jump. Gross Profit Margin for this corporation currently stands at 0.65% with Operating Profit Margin at 0.08%, Pretax Profit Margin comes in at 0.11%, and Net Profit Margin reading is 0.08%. To continue investigating profitability, this company’s Return on Assets is posted at 0.02, Equity is 0.04 and Total Capital is 0.03. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 53.30 points at the first support level, and at 52.91 for the second support level. However, for the 1st resistance point, the stock is sitting at 53.90, and for the 2nd resistance point, it is at 54.11.
Globus Medical Inc [GMED] reported earnings per share of $0.6 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.61/share, meaning a difference of -$0.01 and a surprise factor of -1.60%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $0.57 per share as compared to estimates of $0.57 per share, a difference of $0 representing a surprise of 0.00%.
Ratios To Look Out For
It is important to note that Globus Medical Inc [NYSE:GMED] has a current ratio of 4.88. Further, the Quick Ratio stands at 2.72, while the Cash Ratio is 1.19. Considering the valuation of this stock, the price to sales ratio is 4.63, the price to book ratio is 1.83 and price to earnings (TTM) ratio is 46.09.
Transactions by insiders
Recent insider trading involved Norwalk Leslie V, Director, that happened on Mar 15 ’24 when 10590.0 shares were sold. SVP, GC, Corporate Secretary, Huller Kelly completed a deal on Mar 01 ’24 to sell 7500.0 shares. Meanwhile, Director Lemaitre Dan sold 43450.0 shares on May 15 ’23.
